Predict your next investment

HEALTHCARE | Biotechnology
contrafect.com

See what CB Insights has to offer

Stage

Corporate Minority - P2P | IPO

Total Raised

$38.66M

Market Cap

0.11B

Stock Price

2.86

About ContraFect

ContraFect is a biotechnology company committed to developing technologies, treatments, and products that will target and kill the most virulent and resistant microorganisms-including gram-positive bacteria, such as Staphylococcus (MRSA), and viruses, such as Influenza. These therapeutics will remain active regardless of future resistance to synthetic therapies, such as occurs with antibiotics. ContraFect's Mabs target conserved regions on microbes, bypassing changes in targets due to mutation. Lysins, a class of enzymes that digest the key components of bacteria, the cell wall, kill bacteria instantly upon contact, rendering bacteria incapable of developing resistance.

ContraFect Headquarter Location

28 Wells Avenue

Yonkers, New York, 10701,

United States

212-359-9553

Latest ContraFect News

ContraFect's New Data Presented At NACFC Demonstrate Potential Of Direct Lytic Agents To Treat Pulmonary Infections In Patients With Cystic Fibrosis

Nov 9, 2021

Nov 9, 2021 7:30 AM EST ContraFect's New Data Presented At NACFC Demonstrate Potential Of Direct Lytic Agents To Treat Pulmonary Infections In Patients With Cystic Fibrosis Company's Direct Lytic Agents Lysin CF-370 and Amurin Peptide AM1 Show In Vitro Activity Against Prevalent Gram-Negative Pathogens Associated with Lung Infections in Patients with Cystic Fibrosis Author: YONKERS, N.Y., Nov. 09, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that data from the Company's DLA programs, including lysin CF-370 and amurin peptide AM1, demonstrate the potential for their development as treatments for pulmonary infections associated with cystic fibrosis. These data were recently presented at the North American Cystic Fibrosis Conference (NACFC) which was held virtually from November 2-5, 2021. These direct lytic agents show in vitro activity against the most prevalent Gram-negative pathogens, including multi-drug resistant (MDR) strains commonly associated with pulmonary infections in patients with cystic fibrosis. Nine of these MDR strains were evaluated. Currently, few treatment options exist to address these infections, and persons with cystic fibrosis are even more vulnerable. The data further support the in vitro activity profile of CF-370 and AM1 against specific Gram-negative pathogens, including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Achromobacter spp. Raymond Schuch, Ph.D., Vice President, Research, ContraFect Corporation, delivered the poster presentation entitled " Direct Lytic Agents (DLAs), a Novel Family of Antimicrobial Agents, Exert Potent in vitro Bactericidal Activity Against Gram-negative (GN) Pathogens Which Cause Pulmonary Infections in CF Patients, Including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Achromobacter xylosoxidans". The presentation is available on the Company's website . About Cystic Fibrosis According to the Cystic Fibrosis (CF) Foundation, infections are a problem for people with cystic fibrosis because they can cause fever, difficulty breathing, coughing, and excessive inflammation. A cycle of recurring infections and inflammation gradually destroys lung tissue. People with CF are susceptible to infections from bacteria, viruses, and fungi because abnormally thick, sticky mucus traps these germs in the airways. They also are prone to infections because their mucus and airway liquid does not have the same infection-fighting properties as normal mucus. This abnormal mucus provides an ideal environment for bacteria to form protective layers -- known as biofilms -- that make them more difficult to kill. For more information visit: https://www.cff.org/What-is-CF/About-Cystic-Fibrosis/ About Exebacase (CF-301): Exebacase is an anti-staphylococcal recombinantly-produced lysin (cell wall hydrolase enzyme) with potent bactericidal activity against  Staph aureus, a major cause of bloodstream infections (BSIs) also known as bacteremia. It is the first lysin to enter clinical studies in the U.S. and was granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections, including right-sided endocarditis, when used in addition to standard of care (SOC) anti-staphylococcal antibiotics. Exebacase is currently being studied in the Phase 3 DISRUPT superiority design study of exebacase in patients with  Staph aureus bacteremia, including right-sided endocarditis. In the Company's Phase 2 study of exebacase, a pre-specified analysis of MRSA-infected patients showed that the clinical responder rate at Day 14 in patients treated with exebacase was nearly 43-percentage points higher than in patients treated with SOC antibiotics alone (74.1% for patients treated with exebacase compared to 31.3% for patients treated with SOC antibiotics alone (p=0.010)). In addition to the higher rate of clinical response, MRSA-infected patients treated with exebacase showed a 21-percentage point reduction in 30-day all-cause mortality (p=0.056), a four-day lower median length of hospital stay and meaningful reductions in hospital readmission rates. Exebacase has the potential to be a first-in-class treatment for  Staph aureus bacteremia. The lysin was licensed from The Rockefeller University and is being developed at ContraFect. About ContraFect ContraFect is a biotechnology company focused on the discovery and development of DLAs, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of DLAs, which include lysins and amurin peptides. Lysins are a new class of DLAs which are recombinantly produced antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics. Amurin peptides are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including  P. aeruginosa,  Acinetobacter baumannii, and  Enterobacter species. We believe that the properties of our lysins and amurin peptides will make them suitable for targeting antibiotic-resistant organisms, such as methicillin-resistant Staph aures (MRSA) and  P. aeruginosa, which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. We have completed a Phase 2 clinical trial for the treatment of  Staph aureus bacteremia, including endocarditis, with our lead lysin candidate, exebacase, which is the first lysin to enter clinical studies in the U.S. Exebacase, currently being studied in a pivotal Phase 3 clinical study, was granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections, including right-sided endocarditis, when used in addition to SOC anti-staphylococcal antibiotics. Follow ContraFect on Twitter @ContraFectCorp and LinkedIn . Forward-Looking Statements This press release contains, and our officers and representatives may make from time to time, "forward-looking statements" within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential," "promise" or similar references to future periods. Examples of forward-looking statements in this release include, without limitation, statements regarding: the in-vitro activity of DLAs and their potential to treat pulmonary infections associated with cystic fibrosis, ContraFect's ability to discover and develop DLAs as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, whether ContraFect will address life-threatening infections using its DLA platform, whether lysins are a new class of DLAs which are recombinantly produced, antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics, whether amurins are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, and whether the properties of ContraFect's lysins and amurins will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and  P. aeruginosa. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect's current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect's control, including the occurrence of any adverse events related to the discovery, development and commercialization of ContraFect's product candidates such as unfavorable clinical trial results, insufficient supplies of drug products, the lack of regulatory approval, or the unsuccessful attainment or maintenance of patent protection and other important risks detailed under the caption "Risk Factors" in ContraFect's filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Investor Relations Contacts: Jules AbrahamCORE IRTel: 917-885-7378Email: Julesa@coreir.com By

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing ContraFect

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ContraFect is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

14,140 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

ContraFect Patents

ContraFect has filed 26 patents.

The 3 most popular patent topics include:

  • Antibiotics
  • Bacterial diseases
  • Protein families
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/30/2020

4/27/2021

Antibiotics, Protein families, Molecular biology, Aminoglycoside antibiotics, Bacterial diseases

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

1/30/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

4/27/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Antibiotics, Protein families, Molecular biology, Aminoglycoside antibiotics, Bacterial diseases

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

ContraFect Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

ContraFect Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.